Screener
Xeris Biopharma Holdings, Inc. XERS Keveyis — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue: | ||||
| Recorlev | $56,780 | $31,444 | $106,548 | $56,974 |
| Gvoke | 22,549 | 23,467 | 43,349 | 44,312 |
| Keveyis | 11,675 | 11,485 | 23,561 | 22,912 |
| Other product revenue | — | 1,312 | — | 1,312 |
| Product revenue, net | 91,004 | 67,708 | 173,458 | 125,510 |
| Royalty, contract and other revenue | 1,096 | 3,831 | 1,769 | 6,148 |
| Total revenue | $92,100 | $71,539 | $175,227 | $131,658 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net?
- Xeris Biopharma Holdings, Inc. (XERS) reported keveyis — product revenue, net of $11.68M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net increased by 1.7% year-over-year, from $11.49M to $11.68M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net has grown at a 46.4% compound annual growth rate (CAGR), from $10.36M to $47.65M.
- What does keveyis — product revenue, net mean?
- This metric represents the total net sales generated from the commercialization of a specific therapeutic product after accounting for returns, rebates, and other sales deductions. It serves as a key indicator of the product's market adoption, pricing power, and commercial performance within its specific therapeutic category. Tracking this revenue stream helps investors assess the growth trajectory and lifecycle maturity of the company's specialized pharmaceutical assets.
Ask your AI about Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude